In 2014, Ibrutinib was the first bruton-tyrosine-kinase (BTK) inhibitor to reach the market for treatment of chronic lymphocytic leukemia (CCL) and small lymphocytic lymphoma (SSL). We analyzed CLL/SSL patients newly starting Ibrutinib in our Medicare Advantage (MA) claims data to evaluate rates of Ibrutinib discontinuation and down dosing, new development of adverse events (AEs), and in particular, the incidence of new development of atrial fibrillation. We used 2015-2019 Milliman proprietary claims data from MA with Part D (MAPD). The database contains annual enrollment and all Parts A, B, and D claims for approximately 2.5 million annual members.

This report was commissioned by BeiGene, USA.